Literature DB >> 14599406

[Comparison of population coronary heart disease risk estimated by the Framingham original and REGICOR calibrated functions].

Rafael Ramos1, Pascual Solanas, Ferran Cordón, Izabella Rohlfs, Roberto Elosua, Joan Sala, Rafael Masiá, María Teresa Faixedas, Jaume Marrugat.   

Abstract

BACKGROUND AND
OBJECTIVE: The therapeutic consequences of using the Framingham function calibrated by the REGICOR and Framingham investigators (Framingham-REGICOR) in the Spanish population are unknown. The objective of this study was to determine the differences in the classification of the population coronary risk when using the classical Framingham function (Framingham-Wilson) and that calibrated, and its consequences on the theoretical indication of lipid-lowering treatment. PATIENTS AND
METHOD: The classification into the < 2%, 2-4,9%, 5-9,9%, 10-19,9%, 20-39,9%, and >= 40% risk categories observed by the two functions was compared in 3.270 individuals aged 35 to 74 years with no history of ischaemic heart disease or lipid-lowering drug treatment, recruited in two population samples representative of Girona between 1994 and 2001. The number of lipid-lowering treatment candidates was estimated applying the most recent guidelines for clinical practice, according to the risk level obtained with both functions.
RESULTS: The proportion of patients excluded owing to the fact that they already were on lipid-lowering treatment was 6.2%. The Framingham-REGICOR assigned 54.2% of women and 67.9% of men to a lower level of risk as compared to the Framingham-Wilson function. In 0.2% of women and 21.2% of men the decrease was two categories of risk. The figures in diabetic participants were 75.7 and 18.5%, respectively. When the European recommendations published in 2003 were applied, lipid-lowering treatment would have been indicated in 14.5% and in 4.4% of non-diabetic participants by the Framingham-Wilson and the Framingham-REGICOR, respectively.
CONCLUSIONS: The calibrated Framingham-REGICOR function assigns a lower coronary risk category in more than 50% of women and almost 90% of men than the uncalibrated Framingham function. The calibrated function is more suitable for risk estimation in primary prevention than the original function in Spain.

Entities:  

Mesh:

Year:  2003        PMID: 14599406     DOI: 10.1016/s0025-7753(03)74007-x

Source DB:  PubMed          Journal:  Med Clin (Barc)        ISSN: 0025-7753            Impact factor:   1.725


  8 in total

1.  Original and REGICOR Framingham functions in a nondiabetic population of a Spanish health care center: a validation study.

Authors:  Francisco Buitrago; Juan Ignacio Calvo-Hueros; Lourdes Cañón-Barroso; Gerónimo Pozuelos-Estrada; Luis Molina-Martínez; Manuel Espigares-Arroyo; Juan Antonio Galán-González; Francisco J Lillo-Bravo
Journal:  Ann Fam Med       Date:  2011 Sep-Oct       Impact factor: 5.166

2.  Validity of an adaptation of the Framingham cardiovascular risk function: the VERIFICA Study.

Authors:  Jaume Marrugat; Isaac Subirana; Eva Comín; Carmen Cabezas; Joan Vila; Roberto Elosua; Byung-Ho Nam; Rafel Ramos; Joan Sala; Pascual Solanas; Ferran Cordón; Joan Gené-Badia; Ralph B D'Agostino
Journal:  J Epidemiol Community Health       Date:  2007-01       Impact factor: 3.710

3.  Effectiveness of a physical activity program on cardiovascular disease risk in adult primary health-care users: the "Pas-a-Pas" community intervention trial.

Authors:  Victoria Arija; Felipe Villalobos; Roser Pedret; Angels Vinuesa; Mercé Timón; Teresa Basora; Dolors Aguas; Josep Basora
Journal:  BMC Public Health       Date:  2017-06-15       Impact factor: 3.295

4.  Agreement between the SCORE and D'Agostino Scales for the classification of high cardiovascular risk in sedentary spanish patients.

Authors:  Manuel A Gómez-Marcos; Gonzalo Grandes; José A Iglesias-Valiente; Alvaro Sánchez; Imanol Montoya; Luis García-Ortiz
Journal:  Int J Environ Res Public Health       Date:  2009-11-11       Impact factor: 3.390

5.  Cost-effectiveness analysis of a multiple health behaviour change intervention in people aged between 45 and 75 years: a cluster randomized controlled trial in primary care (EIRA study).

Authors:  Maria Rubio-Valera; Antoni Serrano-Blanco; Ignacio Aznar-Lou; Edurne Zabaleta-Del-Olmo; Marc Casajuana-Closas; Alba Sánchez-Viñas; Elizabeth Parody-Rúa; Bonaventura Bolíbar; Montserrat Iracheta-Todó; Oana Bulilete; Tomàs López-Jiménez; Haizea Pombo-Ramos; María Victoria Martín Miguel; Rosa Magallón-Botaya; Jose Ángel Maderuelo-Fernández; Emma Motrico; Juan Bellón; Ruth Martí-Lluch
Journal:  Int J Behav Nutr Phys Act       Date:  2021-07-02       Impact factor: 6.457

6.  Therapeutic implications of selecting the SCORE (European) versus the D'AGOSTINO (American) risk charts for cardiovascular risk assessment in hypertensive patients.

Authors:  Manuel A Gómez-Marcos; Carlos Martínez-Salgado; Carlos Martin-Cantera; José I Recio-Rodríguez; Yolanda Castaño-Sánchez; Maria Giné-Garriga; Emiliano Rodriguez-Sanchez; Luis García-Ortiz
Journal:  BMC Cardiovasc Disord       Date:  2009-05-11       Impact factor: 2.298

7.  SCORE and REGICOR function charts underestimate the cardiovascular risk in Spanish patients with rheumatoid arthritis.

Authors:  Carmen Gómez-Vaquero; Alfonso Corrales; Andrea Zacarías; Javier Rueda-Gotor; Ricardo Blanco; Carlos González-Juanatey; Javier Llorca; Miguel A González-Gay
Journal:  Arthritis Res Ther       Date:  2013-08-21       Impact factor: 5.156

8.  Complex multiple risk intervention to promote healthy behaviours in people between 45 to 75 years attended in primary health care (EIRA study): study protocol for a hybrid trial.

Authors:  Edurne Zabaleta-Del-Olmo; Haizea Pombo; Mariona Pons-Vigués; Marc Casajuana-Closas; Enriqueta Pujol-Ribera; Tomás López-Jiménez; Carmen Cabezas-Peña; Carme Martín-Borràs; Antoni Serrano-Blanco; Maria Rubio-Valera; Joan Llobera; Alfonso Leiva; Caterina Vicens; Clara Vidal; Manuel Campiñez; Remedios Martín-Álvarez; José-Ángel Maderuelo; José-Ignacio Recio; Luis García-Ortiz; Emma Motrico; Juan-Ángel Bellón; Patricia Moreno-Peral; Carlos Martín-Cantera; Ana Clavería; Susana Aldecoa-Landesa; Rosa Magallón-Botaya; Bonaventura Bolíbar
Journal:  BMC Public Health       Date:  2018-07-13       Impact factor: 3.295

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.